Trial Profile
A Phase I Study to Assess the Safety and Tolerability of Pembrolizumab in Combination With Fixed Rate Gemcitabine Chemotherapy in Patients With Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Leiomyosarcoma; Malignant fibrous histiocytoma
- Focus Adverse reactions
- Acronyms GEMMK
- 29 Jun 2021 Planned End Date changed from 1 Dec 2020 to 5 Feb 2023.
- 29 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 18 May 2020 Status changed from active, no longer recruiting to recruiting.